[Skip to Content]
[Skip to Content Landing]
July 22, 1992


Author Affiliations

Klinik und Poliklinik für Nuklearmedizin Universität Würzburg (Germany)

JAMA. 1992;268(4):474-475. doi:10.1001/jama.1992.03490040050022

To the Editor.  —The issues surrounding dual-energy x-ray absorptiometry (DEXA) may have an impact in Germany, as these devices have been launched in Germany in quite large numbers.1 As members of the German advisory board for quality assurance in nuclear medicine and radiology instrumentation, we would like to comment on this report.We are able to confirm the figures for the precision of DEXA cited in the article and the specification of its inaccuracies. But we do not agree with the conclusions drawn.For 2½ years we have been using DEXA for comparison during the clinical evaluation of a peripheral quantitative computed tomography (pQCT) system, which was commercialized 4 years ago. The pQCT has met with a large demand in Germany. The method has been well described and clinically evaluated,2,3 and it is reimbursed by the public health care program. There is now increasing interest in it in